"Pravastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).
| Descriptor ID |
D017035
|
| MeSH Number(s) |
D02.455.426.559.847.638.930 D04.615.638.930
|
| Concept/Terms |
Pravachol- Pravachol
- Elisor
- Selektine
- Lipostat
- Pravacol
- Pravasin
SQ-31000- SQ-31000
- SQ 31000
- SQ31000
- SQ-31,000
- SQ 31,000
- SQ31,000
|
Below are MeSH descriptors whose meaning is more general than "Pravastatin".
Below are MeSH descriptors whose meaning is more specific than "Pravastatin".
This graph shows the total number of publications written about "Pravastatin" by people in this website by year, and whether "Pravastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Pravastatin" by people in Profiles.
-
Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Ann Intern Med. 2019 01 01; 170(1):1-10.
-
Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Press Cardiovasc Prev. 2018 Dec; 25(4):355-359.
-
Statin Use is Not Associated with Future Long-Term Care Admission: Extended Follow-Up of Two Randomised Controlled Trials. Drugs Aging. 2018 07; 35(7):657-663.
-
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017 07; 4(7):e284-e294.
-
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017 03 27; 31(6):797-806.
-
Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011. Int J Cardiol. 2017 Mar 01; 230:592-598.
-
Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2015 Sep 04; 10(9):1534-41.
-
Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther. 2007 Sep; 322(3):1324-32.
-
Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis. 2003 Jun; 168(2):289-95.
-
[Statins as new therapeutic possibility in osteoporosis?]. Dtsch Med Wochenschr. 2001 May 11; 126(19):565-8.